Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMAB™, the Company’s proprietary antibody drug discovery platform.
APGN
0.4753 as of 3/29/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 3/24/2020 | Series C | $343.82MM | $XXX.XX | $XXX.XX |
| 8/8/2018 | Series B | $115.22MM | $XXX.XX | $XXX.XX |
| 8/8/2013 | Series A-1 and A-2 | $48.43MM | $XXX.XX | $XXX.XX |
